# Volitionrx Ltd: financial statements, quarterly

VNRX · NYSE · CIK 93314 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vnrx.md) · [Financials](/companies/vnrx/financials.md) · [Filings](/companies/vnrx/filings.md) · [Insiders](/companies/vnrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vnrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [165](/filings/0001477932-24-007207.md) | [244 d](/filings/0001477932-25-002231.md) | [172](/filings/0001477932-25-003853.md) | [396](/filings/0001477932-25-005923.md) | [475](/filings/0001477932-25-008186.md) | [192 d](/filings/0001477932-26-001832.md) | [246](/filings/0001477932-26-003128.md) | [407](/filings/0001477932-26-004995.md) | [627](/filings/0001477932-25-008186.md) | [447 d](/filings/0001477932-26-001832.md) | [985](/filings/0001477932-26-003128.md) | [399](/filings/0001477932-26-004995.md) |
| Research and development | $k | [4,651](/filings/0001477932-24-007207.md) | [4,544 d](/filings/0001477932-25-002231.md) | [4,630](/filings/0001477932-25-003853.md) | [3,716](/filings/0001477932-25-005923.md) | [3,474](/filings/0001477932-25-008186.md) | [2,587 d](/filings/0001477932-26-001832.md) | [2,607](/filings/0001477932-26-003128.md) | [2,720](/filings/0001477932-26-004995.md) | [2,286](/filings/0001477932-25-008186.md) | [2,468 d](/filings/0001477932-26-001832.md) | [2,852](/filings/0001477932-26-003128.md) | [1,801](/filings/0001477932-26-004995.md) |
| Operating income | $k | [(8,653)](/filings/0001477932-24-007207.md) | [(8,741) d](/filings/0001477932-25-002231.md) | [(8,385)](/filings/0001477932-25-003853.md) | [(6,990)](/filings/0001477932-25-005923.md) | [(5,869)](/filings/0001477932-25-008186.md) | [(5,781) d](/filings/0001477932-26-001832.md) | [(5,522)](/filings/0001477932-26-003128.md) | [(6,298)](/filings/0001477932-26-004995.md) | [(5,101)](/filings/0001477932-25-008186.md) | [(4,818) d](/filings/0001477932-26-001832.md) | [(5,349)](/filings/0001477932-26-003128.md) | [(4,156)](/filings/0001477932-26-004995.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | [96.7](/filings/0001477932-26-003128.md) | [123](/filings/0001477932-26-004995.md) | not reported | not reported | [126](/filings/0001477932-26-003128.md) | [740](/filings/0001477932-26-004995.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(8,453)](/filings/0001477932-24-007207.md) | [(8,800) d](/filings/0001477932-25-002231.md) | [(8,367)](/filings/0001477932-25-003853.md) | [(6,986)](/filings/0001477932-25-005923.md) | [(5,822)](/filings/0001477932-25-008186.md) | [(5,793) d](/filings/0001477932-26-001832.md) | [(5,424)](/filings/0001477932-26-003128.md) | [(6,284)](/filings/0001477932-26-004995.md) | [(5,378)](/filings/0001477932-25-008186.md) | [(6,271) d](/filings/0001477932-26-001832.md) | [(6,665)](/filings/0001477932-26-003128.md) | [(7,326)](/filings/0001477932-26-004995.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.10)](/filings/0001477932-25-003853.md) | [(0.08)](/filings/0001477932-25-005923.md) | [(0.07)](/filings/0001477932-25-008186.md) | not reported | [(1.12)](/filings/0001477932-26-003128.md) | [(1.22)](/filings/0001477932-26-004995.md) | [(0.05)](/filings/0001477932-25-008186.md) | not reported | [(0.97)](/filings/0001477932-26-003128.md) | [(0.85)](/filings/0001477932-26-004995.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.8](/filings/0001477932-23-008451.md) | [20.7](/filings/0001477932-25-002231.md) | [11.8](/filings/0001477932-24-002775.md) | not reported | not reported | [3.3](/filings/0001477932-26-001832.md) | [2.6](/filings/0001477932-25-003853.md) | [2.3](/filings/0001477932-25-005923.md) | [0.2](/filings/0001477932-25-008186.md) | [1.1](/filings/0001477932-26-001832.md) | not reported | [2.8](/filings/0001477932-26-004995.md) |
| Current assets | $m | [12.2](/filings/0001477932-23-008451.md) | [21.9](/filings/0001477932-25-002231.md) | [13.5](/filings/0001477932-24-002775.md) | [7.3](/filings/0001477932-24-004842.md) | [6.8](/filings/0001477932-24-007207.md) | [4.1](/filings/0001477932-26-001832.md) | [3.3](/filings/0001477932-25-003853.md) | [3.3](/filings/0001477932-25-005923.md) | [1.3](/filings/0001477932-25-008186.md) | [2.1](/filings/0001477932-26-004995.md) | [4.5](/filings/0001477932-26-003128.md) | [4.1](/filings/0001477932-26-004995.md) |
| Total assets | $m | [18.0](/filings/0001477932-23-008451.md) | [28.0](/filings/0001477932-25-002231.md) | [19.4](/filings/0001477932-24-002775.md) | [13.1](/filings/0001477932-24-004842.md) | [12.7](/filings/0001477932-24-007207.md) | [9.4](/filings/0001477932-26-001832.md) | [8.5](/filings/0001477932-25-003853.md) | [8.7](/filings/0001477932-25-005923.md) | [6.4](/filings/0001477932-25-008186.md) | [6.9](/filings/0001477932-26-004995.md) | [9.0](/filings/0001477932-26-003128.md) | [8.3](/filings/0001477932-26-004995.md) |
| Current liabilities | $m | [17.7](/filings/0001477932-23-008451.md) | [8.9](/filings/0001477932-25-002231.md) | [31.5](/filings/0001477932-24-002775.md) | [31.0](/filings/0001477932-24-004842.md) | [30.3](/filings/0001477932-24-007207.md) | [7.8](/filings/0001477932-26-001832.md) | [8.3](/filings/0001477932-25-003853.md) | [9.2](/filings/0001477932-25-005923.md) | [11.4](/filings/0001477932-25-008186.md) | [12.2](/filings/0001477932-26-004995.md) | [13.6](/filings/0001477932-26-003128.md) | [13.5](/filings/0001477932-26-004995.md) |
| Total liabilities | $m | [20.9](/filings/0001477932-23-008451.md) | [36.7](/filings/0001477932-25-002231.md) | [36.1](/filings/0001477932-24-002775.md) | [36.0](/filings/0001477932-24-004842.md) | [35.3](/filings/0001477932-24-007207.md) | [35.5](/filings/0001477932-26-001832.md) | [37.5](/filings/0001477932-25-003853.md) | [41.8](/filings/0001477932-25-005923.md) | [42.4](/filings/0001477932-25-008186.md) | [42.5](/filings/0001477932-26-004995.md) | [42.4](/filings/0001477932-26-003128.md) | [41.8](/filings/0001477932-26-004995.md) |
| Long-term debt | $m | [2.1](/filings/0001477932-23-008451.md) | [3.6](/filings/0001477932-25-002231.md) | [3.4](/filings/0001477932-24-002775.md) | [3.9](/filings/0001477932-24-004842.md) | [3.8](/filings/0001477932-24-007207.md) | [4.0](/filings/0001477932-26-001832.md) | [5.5](/filings/0001477932-25-003853.md) | [5.8](/filings/0001477932-25-005923.md) | [5.6](/filings/0001477932-25-008186.md) | [5.8](/filings/0001477932-26-004995.md) | [6.4](/filings/0001477932-26-003128.md) | [6.0](/filings/0001477932-26-004995.md) |
| Current portion of debt | $m | [1.3](/filings/0001477932-23-008451.md) | [1.2](/filings/0001477932-25-002231.md) | [1.1](/filings/0001477932-24-002775.md) | [1.0](/filings/0001477932-24-004842.md) | [1.0](/filings/0001477932-24-007207.md) | [0.9](/filings/0001477932-26-001832.md) | [0.9](/filings/0001477932-25-003853.md) | [1.0](/filings/0001477932-25-005923.md) | [0.9](/filings/0001477932-25-008186.md) | [0.9](/filings/0001477932-26-004995.md) | [0.9](/filings/0001477932-26-003128.md) | [1.1](/filings/0001477932-26-004995.md) |
| Shareholders' equity | $m | [(2.0)](/filings/0001477932-23-008451.md) | [(7.8)](/filings/0001477932-25-002231.md) | [(15.6)](/filings/0001477932-24-002775.md) | [(21.8)](/filings/0001477932-24-004842.md) | [(21.5)](/filings/0001477932-24-007207.md) | [(24.9)](/filings/0001477932-26-001832.md) | [(27.8)](/filings/0001477932-25-003853.md) | [(31.8)](/filings/0001477932-25-005923.md) | [(34.6)](/filings/0001477932-25-008186.md) | [(34.2)](/filings/0001477932-26-004995.md) | [(32.0)](/filings/0001477932-26-003128.md) | [(32.2)](/filings/0001477932-26-004995.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(8,418) d](/filings/0001477932-24-007207.md) | [6,448 d](/filings/0001477932-25-002231.md) | [(8,342)](/filings/0001477932-25-003853.md) | [(6,732) d](/filings/0001477932-25-005923.md) | [(5,387) d](/filings/0001477932-25-008186.md) | [(5,432) d](/filings/0001477932-26-001832.md) | [(4,298)](/filings/0001477932-26-003128.md) | [(6,263) d](/filings/0001477932-26-004995.md) | [(3,631) d](/filings/0001477932-25-008186.md) | [(5,492) d](/filings/0001477932-26-001832.md) | [(5,280)](/filings/0001477932-26-003128.md) | [(5,160) d](/filings/0001477932-26-004995.md) |
| Capital expenditure | $k | [273 d](/filings/0001477932-24-007207.md) | [309 d](/filings/0001477932-25-002231.md) | [28.8](/filings/0001477932-25-003853.md) | [39.4 d](/filings/0001477932-25-005923.md) | [137 d](/filings/0001477932-25-008186.md) | [72.6 d](/filings/0001477932-26-001832.md) | [1.8](/filings/0001477932-26-003128.md) | [76.8 d](/filings/0001477932-26-004995.md) | [0.0 d](/filings/0001477932-25-008186.md) | [11.0 d](/filings/0001477932-26-001832.md) | [9.2](/filings/0001477932-26-003128.md) | [1.8 d](/filings/0001477932-26-004995.md) |
| Share repurchases | $k | [0.0 d](/filings/0001477932-24-007207.md) | [0.0 d](/filings/0001477932-25-002231.md) | [0.0](/filings/0001477932-24-002775.md) | [0.0 d](/filings/0001477932-24-004842.md) | [0.0 d](/filings/0001477932-24-007207.md) | [0.0 d](/filings/0001477932-25-002231.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2014 (2014-06-30) | Q3 FY2014 (2014-09-30) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.9](/filings/0001078782-15-001246.md) | [13.5](/filings/0001078782-15-001736.md) | [17.9](/filings/0001078782-15-001246.md) | [18.0](/filings/0001078782-15-001736.md) | [82.0](/filings/0001477932-25-003853.md) | [82.7](/filings/0001477932-25-005923.md) | [87.9](/filings/0001477932-25-008186.md) | [4.8](/filings/0001477932-26-003128.md) | [5.1](/filings/0001477932-26-004995.md) | [108](/filings/0001477932-25-008186.md) | [6.9](/filings/0001477932-26-003128.md) | [9.2](/filings/0001477932-26-004995.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,649,384 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001477932-26-004995.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.